Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA

Share this content:
Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA
Durvalumab Extends Survival in Stage III Non-Small Cell Lung CA

MONDAY, Oct. 29, 2018 (HealthDay News) -- Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, according to a study published Sept. 25 in the New England Journal of Medicine.

Scott J. Antonia, M.D., Ph.D., from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues randomly assigned patients in a two-to-one ratio to receive durvalumab (n = 473) intravenously (10 mg per kilogram of body weight) or placebo (n = 236) every two weeks for up to 12 months.

The researchers found that the 24-month overall survival rate was 66.3 percent in the durvalumab group versus 55.6 percent in the placebo group (two-sided P = 0.005). Overall survival was significantly prolonged with durvalumab versus placebo (stratified hazard ratio [HR] for death, 0.68; P = 0.0025). For progression-free survival, the median duration was 17.2 months in the durvalumab group and 5.6 months in the placebo group (stratified HR for disease progression or death, 0.51). The median time to death or distant metastasis was 28.3 months in the durvalumab group and 16.2 months in the placebo group (stratified HR, 0.53). Grade 3 or 4 adverse events of any cause occurred in 30.5 percent of the patients in the durvalumab group and 26.1 percent in the placebo group. In addition, 15.4 percent and 9.8 percent of the patients, respectively, discontinued the trial regimen because of adverse events.

"Adding durvalumab to the standard treatment has made a big impact for this group of patients," Antonia said in a statement. "It's allowing them to live longer and potentially increasing their chance for cure."

Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which supported the study.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Quick New Ebola Test Approved by FDA

Quick New Ebola Test Approved by FDA

Administration authorizes emergency use of first Ebola fingerstick test with portable reader

CDC: Gun Deaths on the Rise in the United States

CDC: Gun Deaths on the Rise in the ...

U.S. has world's highest rate of gun ownership by civilians among industrialized countries

FDA to Ban Most Flavored Electronic Cigarettes

FDA to Ban Most Flavored Electronic Cigarettes

Details of the ban expected to be announced next week

is free, fast, and customized just for you!




Already a member?

Sign In Now »